183 related articles for article (PubMed ID: 30943495)
1. Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours.
Trouillas J; Delgrange E; Wierinckx A; Vasiljevic A; Jouanneau E; Burman P; Raverot G
Neuroendocrinology; 2019; 109(1):70-76. PubMed ID: 30943495
[TBL] [Abstract][Full Text] [Related]
2. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
3. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
[TBL] [Abstract][Full Text] [Related]
4. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Raverot G; Jouanneau E; Trouillas J
Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours.
Simon J; Perez-Rivas LG; Zhao Y; Chasseloup F; Lasolle H; Cortet C; Descotes F; Villa C; Baussart B; Burman P; Maiter D; von Selzam V; Rotermund R; Flitsch J; Thorsteinsdottir J; Jouanneau E; Buchfelder M; Chanson P; Raverot G; Theodoropoulou M
Eur J Endocrinol; 2023 Sep; 189(3):372-378. PubMed ID: 37721395
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
Biagetti B; Simò R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
[TBL] [Abstract][Full Text] [Related]
7. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
8. Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability.
Wierinckx A; Delgrange E; Bertolino P; François P; Chanson P; Jouanneau E; Lachuer J; Trouillas J; Raverot G
Front Endocrinol (Lausanne); 2018; 9():706. PubMed ID: 30555413
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J;
J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287
[TBL] [Abstract][Full Text] [Related]
10. Activin-inhibitory action on lactotrophs is decreased in lactotroph hyperplasia.
Faraoni EY; Abeledo Machado AI; Pérez PA; Marcial López CA; Camilletti MA; Peña-Zanoni M; Rulli SB; Gutiérrez S; Díaz-Torga G
J Endocrinol; 2020 Feb; 244(2):415-429. PubMed ID: 32395971
[TBL] [Abstract][Full Text] [Related]
11. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
Trouillas J; Roy P; Sturm N; Dantony E; Cortet-Rudelli C; Viennet G; Bonneville JF; Assaker R; Auger C; Brue T; Cornelius A; Dufour H; Jouanneau E; François P; Galland F; Mougel F; Chapuis F; Villeneuve L; Maurage CA; Figarella-Branger D; Raverot G; ; Barlier A; Bernier M; Bonnet F; Borson-Chazot F; Brassier G; Caulet-Maugendre S; Chabre O; Chanson P; Cottier JF; Delemer B; Delgrange E; Di Tommaso L; Eimer S; Gaillard S; Jan M; Girard JJ; Lapras V; Loiseau H; Passagia JG; Patey M; Penfornis A; Poirier JY; Perrin G; Tabarin A
Acta Neuropathol; 2013 Jul; 126(1):123-35. PubMed ID: 23400299
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.
Mahboobifard F; Bidari-Zerehpoosh F; Davoudi Z; Panahi M; Dargahi L; Pourgholami MH; Sharifi G; Izadi N; Jorjani M
Pituitary; 2020 Jun; 23(3):232-245. PubMed ID: 32026205
[TBL] [Abstract][Full Text] [Related]
13. [Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics].
Fedorova NS; Abrosimov AY; Dzeranova LK; Pigarova EA; Dedov II
Arkh Patol; 2018; 80(3):34-39. PubMed ID: 29927438
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas.
Jia W; Sander AJ; Jia G; Ni M; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Sep; 33(9):3815-22. PubMed ID: 24023314
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas.
Simpson DJ; Fryer AA; Grossman AB; Wass JA; Pfeifer M; Kros JM; Clayton RN; Farrell WE
Carcinogenesis; 2001 Nov; 22(11):1801-7. PubMed ID: 11698342
[TBL] [Abstract][Full Text] [Related]
16. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.
Principe M; Chanal M; Karam V; Wierinckx A; Mikaélian I; Gadet R; Auger C; Raverot V; Jouanneau E; Vasiljevic A; Hennino A; Raverot G; Bertolino P
Endocr Relat Cancer; 2018 Sep; 25(9):795-806. PubMed ID: 30012586
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Sullivan N; Esiri MM; Wass JA
Clin Endocrinol (Oxf); 2000 Sep; 53(3):337-44. PubMed ID: 10971451
[TBL] [Abstract][Full Text] [Related]
18. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Ben-Shlomo A; Cooper O
Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):301-305. PubMed ID: 28520590
[TBL] [Abstract][Full Text] [Related]
19. Aggressive and Malignant Prolactinomas.
Olarescu NC; Perez-Rivas LG; Gatto F; Cuny T; Tichomirowa MA; Tamagno G; Gahete MD;
Neuroendocrinology; 2019; 109(1):57-69. PubMed ID: 30677777
[TBL] [Abstract][Full Text] [Related]
20. Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: A unique description.
Barresi V; Lionti S; Raso A; Esposito F; Cannavò S; Angileri FF
Neuropathology; 2018 Jun; 38(3):260-267. PubMed ID: 29110337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
